People: Acorda Therapeutics Inc (ACOR.O)
7 Dec 2016
Mr. Andrew Hindman is Chief Business Development Officer of the Company. Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, he held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences. Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa from Wesleyan University, and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.
|Total Annual Compensation, USD||476,986|
|Restricted Stock Awards, USD||1,685,520|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||3,005,160|
|Fiscal Year Total, USD||5,167,670|